Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
169.70
+2.79 (1.67%)
Dec 5, 2025, 4:00 PM EST - Market closed
Jazz Pharmaceuticals Revenue
Jazz Pharmaceuticals had revenue of $1.13B in the quarter ending September 30, 2025, with 6.74% growth. This brings the company's revenue in the last twelve months to $4.16B, up 4.14% year-over-year. In the year 2024, Jazz Pharmaceuticals had annual revenue of $4.07B with 6.12% growth.
Revenue (ttm)
$4.16B
Revenue Growth
+4.14%
P/S Ratio
2.48
Revenue / Employee
$1,484,940
Employees
2,800
Market Cap
10.31B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.07B | 234.75M | 6.12% |
| Dec 31, 2023 | 3.83B | 174.83M | 4.78% |
| Dec 31, 2022 | 3.66B | 565.14M | 18.26% |
| Dec 31, 2021 | 3.09B | 730.67M | 30.91% |
| Dec 31, 2020 | 2.36B | 201.81M | 9.34% |
| Dec 31, 2019 | 2.16B | 270.84M | 14.32% |
| Dec 31, 2018 | 1.89B | 272.23M | 16.82% |
| Dec 31, 2017 | 1.62B | 130.72M | 8.79% |
| Dec 31, 2016 | 1.49B | 163.17M | 12.32% |
| Dec 31, 2015 | 1.32B | 151.93M | 12.95% |
| Dec 31, 2014 | 1.17B | 300.45M | 34.44% |
| Dec 31, 2013 | 872.42M | 286.44M | 48.88% |
| Dec 31, 2012 | 585.98M | 313.70M | 115.21% |
| Dec 31, 2011 | 272.28M | 98.50M | 56.68% |
| Dec 31, 2010 | 173.78M | 45.33M | 35.29% |
| Dec 31, 2009 | 128.45M | 60.94M | 90.26% |
| Dec 31, 2008 | 67.51M | 2.21M | 3.39% |
| Dec 31, 2007 | 65.30M | 20.45M | 45.58% |
| Dec 31, 2006 | 44.86M | 23.41M | 109.20% |
| Dec 31, 2005 | 21.44M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
JAZZ News
- 1 day ago - Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting - PRNewsWire
- 1 day ago - Trials, Sales Wins Sends Jazz Pharmaceuticals Higher - FXEmpire
- 4 days ago - Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium - PRNewsWire
- 4 days ago - Jazz Pharmaceuticals plc (JAZZ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 18 days ago - Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference - PRNewsWire
- 19 days ago - Jazz Pharmaceuticals: Stock Soars On Zanidatamab Data - I'm Still On The Fence - Seeking Alpha
- 19 days ago - Jazz Pharmaceuticals' And Zymeworks' Ziihera Success: A Pleasant Surprise - Seeking Alpha
- 19 days ago - Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans - Benzinga